66 related articles for article (PubMed ID: 38730986)
1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A; Guven DC; Koksal B; Karaoglan BB; Kivrak D; Ismayilov R; Aslan F; Sutcuoglu O; Yazici O; Kadioglu A; Alan O; Majidova N; Erciyestepe M; Ozcan E; Akdag G; Taban H; Kaya AO; Guliyev M; Yildirim N; Sakalar T; Yazilitas D; Unal C; On S; Biter S; Demirci NS; Senler FC; Kemal Y; Halil OD; Gullu I; Aksoy S
Eur Arch Otorhinolaryngol; 2024 May; ():. PubMed ID: 38795147
[TBL] [Abstract][Full Text] [Related]
2. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Suzuki S; Taguchi Y; Kitabayashi T; Sato N; Kaya H; Abe T; Endo T; Suzuki H; Kawasaki Y; Yamada T
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38730986
[No Abstract] [Full Text] [Related]
3. Ultra-high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma.
Saito Y; Kobayashi K; Fukuoka O; Sakai T; Yamamura K; Ando M; Kondo K
Head Neck; 2024 Feb; 46(2):367-377. PubMed ID: 38063247
[TBL] [Abstract][Full Text] [Related]
4. The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy.
Mortezaee K; Majidpoor J; Kharazinejad E
Biomed Pharmacother; 2023 Jun; 162():114646. PubMed ID: 37011483
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.
Meliante PG; Zoccali F; de Vincentiis M; Ralli M; Petrella C; Fiore M; Minni A; Barbato C
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900006
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Serum Albumin Level and Albumin-Based Mono- and Combination Biomarkers in Patients with Hepatocellular Carcinoma.
Jeng LB; Chan WL; Teng CF
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831351
[TBL] [Abstract][Full Text] [Related]
7. Reliability of patient-reported toxicities during adjuvant chemotherapy.
Cremante M; Pastorino A; Ponzano M; Grassi M; Martelli V; Puccini A; Catalano F; Murianni V; Iaia ML; Puglisi S; Gandini A; Fornarini G; Caprioni F; Andretta V; Pessino A; Comandini D; Sciallero MS; Mammoliti S; Sormani MP; Sobrero A
Eur J Cancer; 2023 Mar; 182():115-121. PubMed ID: 36758476
[TBL] [Abstract][Full Text] [Related]
8. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A; Burtness B
Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
[TBL] [Abstract][Full Text] [Related]
9. Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Suzuki S; Abe T; Endo T; Kaya H; Kitabayashi T; Kawasaki Y; Yamada T
Cancer Manag Res; 2022; 14():3293-3302. PubMed ID: 36452436
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers.
Ettl T; Grube M; Schulz D; Bauer RJ
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291769
[TBL] [Abstract][Full Text] [Related]
11. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Ghosh S; Shah PA; Johnson FM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887235
[TBL] [Abstract][Full Text] [Related]
12. Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years.
Matsuo M; Yasumatsu R; Masuda M; Yamauchi M; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
In Vivo; 2022; 36(4):1881-1886. PubMed ID: 35738615
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.
Park JC; Krishnakumar HN; Saladi SV
Curr Oncol; 2022 Jun; 29(6):4185-4198. PubMed ID: 35735443
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Jayaprakash V; Wei L; Ferris RL
Oncologist; 2022 Mar; 27(2):e194-e198. PubMed ID: 35641218
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors in Cancer Therapy.
Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
[TBL] [Abstract][Full Text] [Related]
16. Low serum albumin: A neglected predictor in patients with cardiovascular disease.
Manolis AA; Manolis TA; Melita H; Mikhailidis DP; Manolis AS
Eur J Intern Med; 2022 Aug; 102():24-39. PubMed ID: 35537999
[TBL] [Abstract][Full Text] [Related]
17. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
[TBL] [Abstract][Full Text] [Related]
18. Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
Shimamura SS; Shukuya T; Asao T; Hayakawa D; Kurokawa K; Xu S; Miura K; Mitsuishi Y; Tajima K; Shibayama R; Shimada N; Takahashi F; Takahashi K
BMC Cancer; 2022 Mar; 22(1):323. PubMed ID: 35337281
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
